» Articles » PMID: 35037935

Surveillance Improves Outcomes for Carriers of SDHB Pathogenic Variants: A Multicenter Study

Overview
Specialty Endocrinology
Date 2022 Jan 17
PMID 35037935
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Carriers of succinate dehydrogenase type B (SDHB) pathogenic variants (PVs) are at risk of pheochromocytoma and paraganglioma (PPGL) from a young age. It is widely recommended carriers enter a surveillance program to detect tumors, but there are limited studies addressing outcomes of surveillance protocols for SDHB PV carriers.

Objective: The purpose of this study was to describe surveillance-detected (s-d) tumors in SDHB PV carriers enrolled in a surveillance program and to compare their outcomes to probands.

Methods: This was a multicenter study of SDHB PV carriers with at least 1 surveillance episode (clinical, biochemical, imaging) in Australian genetics clinics. Data were collected by both retrospective and ongoing prospective follow-up. Median duration of follow-up was 6.0 years.

Results: 181 SDHB PV carriers (33 probands and 148 nonprobands) were assessed. Tumors were detected in 20% of nonprobands undergoing surveillance (age range 9-76 years). Estimated 10-year metastasis-free survival was 66% for probands and 84% for nonprobands with s-d tumors (P = .027). S-d tumors were smaller than those in probands (median 27 mm vs 45 mm respectively, P = .001). Tumor size ≥40 mm was associated with progression to metastatic disease (OR 16.9, 95% CI 2.3-187.9, P = .001). Patients with s-d tumors had lower mortality compared to probands: 10-year overall survival was 79% for probands and 100% for nonprobands (P = .029).

Conclusion: SDHB carriers with s-d tumors had smaller tumors, reduced risk of metastatic disease, and lower mortality than probands. Our results suggest that SDHB PV carriers should undertake surveillance to improve clinical outcomes.

Citing Articles

Management and follow-up strategies for patients with head and neck paraganglioma.

Richter S, Pacak K, Kunst H, Januszewicz A, Nolting S, Remde H Eur J Endocrinol. 2024; 191(4):389-398.

PMID: 39303070 PMC: 11443905. DOI: 10.1093/ejendo/lvae113.


International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents.

Casey R, Hendriks E, Deal C, Waguespack S, Wiegering V, Redlich A Nat Rev Endocrinol. 2024; 20(12):729-748.

PMID: 39147856 DOI: 10.1038/s41574-024-01024-5.


Identification of Succinate Dehydrogenase Gene Variant Carriers by Blood Biomarkers.

Gebhardt M, Kunath C, Frobel D, Funk A, Peitzsch M, Nolting S J Endocr Soc. 2024; 8(9):bvae142.

PMID: 39145115 PMC: 11323779. DOI: 10.1210/jendso/bvae142.


Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles.

Flynn A, Pattison A, Balachander S, Boehm E, Bowen B, Dwight T Res Sq. 2024; .

PMID: 38978571 PMC: 11230496. DOI: 10.21203/rs.3.rs-4410500/v1.


[Ga]DOTATOC PET-derived radiomics to predict genetic background of head and neck paragangliomas: a pilot investigation.

Pepponi M, Berti V, Fasciglione E, Montanini F, Canu L, Hubele F Eur J Nucl Med Mol Imaging. 2024; 51(9):2684-2694.

PMID: 38687372 DOI: 10.1007/s00259-024-06735-5.


References
1.
van Hulsteijn L, Dekkers O, Hes F, Smit J, Corssmit E . Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. J Med Genet. 2012; 49(12):768-76. DOI: 10.1136/jmedgenet-2012-101192. View

2.
Benn D, Gimenez-Roqueplo A, Reilly J, Bertherat J, Burgess J, Byth K . Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2005; 91(3):827-36. DOI: 10.1210/jc.2005-1862. View

3.
Tufton N, Shapiro L, Srirangalingam U, Richards P, Sahdev A, Kumar A . Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers. Clin Endocrinol (Oxf). 2016; 86(2):286-296. DOI: 10.1111/cen.13246. View

4.
Amar L, Pacak K, Steichen O, Akker S, Aylwin S, Baudin E . International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021; 17(7):435-444. PMC: 8205850. DOI: 10.1038/s41574-021-00492-3. View

5.
Rijken J, van Hulsteijn L, Dekkers O, Niemeijer N, Leemans C, Eijkelenkamp K . Increased Mortality in but Not in Pathogenic Variant Carriers. Cancers (Basel). 2019; 11(1). PMC: 6356820. DOI: 10.3390/cancers11010103. View